All In Biotech

Drug Trial Radar · NCT01232504

Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT

Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial

Last checked: Nov 19, 2026Latest source record: Nov 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Sep 2009

Primary completion

Mar 2013

Study completion Jun 2013

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Jiao Tong University Affiliated First People's Hospital
First posted
Nov 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We conducted a prospective, multicenter, open-label randomized trial to compare the antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF), Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) or a combination of rhGM-CSF and rhG-CSF for neutropenic patients undergoing allogeneic stem cell transplantation.

Conditions

  • Mycoses

Interventions

  • rhGM-CSF groupDrug

    subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).

  • rhG-CSF+rhGM-CSF groupDrug

    a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).

  • rhG-CSF groupDrug

    subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences of Invasive Fungal Diseases (IFD)Time frame: 100 day post transplant

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Wuhan Tongji Hospital

    Wuhan, Hubei, China

  • Shanghai First People's Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.